Atossa遺傳學 ATOS 深 滬
已收盤 09-05 16:00:00 美东时间
0.788
+0.017
+2.18%
華盛通- 最 高0.798
- 今 開0.78
- 成交量 55.89万股
- 最 低 0.7701
- 昨 收 0.7712
- 總市值 1.02亿
- 52周最高 1.66
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 0.5526
- 委 比 77.01%
- 總股本 1.29亿
- 歷史最高 2232.00
- 量 比 1.54
- 振 幅 3.62%
- 歷史最低 0.50
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenon Medical's MAINSAIL Study Shows Significant 12-Month Improvements In Pain, Disability, And Fusion Rates With Catamaran SI Joint Fusion System
~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~~ 83% of Patients Reaching 12 Month
09-04 20:38
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
Atossa Therapeutics ( ($ATOS) ) just unveiled an announcement. On February 21, ...
08-22 04:39
Atossa Therapeutics Selects PSI To Manage FDA-Guided (Z)-Endoxifen Dose-Ranging Study In Metastatic Breast Cancer Ahead Of Phase 3
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025Topline results anticipated in 2026 Positions Atossa for transition into registrational Phase 3 developmentSEATTLE, Aug. 20, 2025
08-20 20:31
Atossa Therapeutics Q2 EPS $(0.07) Misses $(0.06) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 20.69 percent. This is a 40 percent decrease over losses of $(0.05) per share
08-12 20:38
Atossa Therapeutics shares are trading higher after the company announced FDA feedback on its proposed dose optimization trial for (Z)-Endoxifen in ER+/HER2- metastatic breast cancer.
Atossa Therapeutics shares are trading higher after the company announced FDA f...
07-29 19:46
姬广绪｜技术系统的在地性重构：从东京通勤梦魇到中国县域骑手的生存智慧
《通勤梦魇：东京地铁与机器的人类学》，迈克尔·菲什著，孟超、桑元峰译，上海人民出版社2025年1月出版，384页，69.00元 迈克尔·菲什在《通勤梦魇：东京地...
06-25 11:46
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
Craig-Hallum Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
Craig-Hallum analyst Albert Lowe initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $4.
06-06 01:15
Occidental, ADNOC's XRG Eye $500 Million Texas Carbon Capture Venture
Occidental teams up with ADNOC's XRG on a potential $500M carbon capture project in Texas during Trump's UAE visit.
05-16 23:58
